Clinical Practice Guidelines
(Endorsed, December 2016)
The updated guideline, Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus, was developed by the American College of Physicians and was endorsed by the American Academy of Family Physicians.
- Metformin should be prescribed for patients with type 2 diabetes when pharmacologic therapy is needed to improve glycemic control.
- A sulfonylurea, thiazolidinedione, SGLT-2 inhibitor, or DPP-4 inhibitor should be considered when a second oral medication is added to improve glycemic control. Selection of a second agent should be based on a discussion of benefits, adverse effects, and costs.
These guidelines are provided only as assistance for physicians making clinical decisions regarding the care of their patients. As such, they cannot substitute the individual judgment brought to each clinical situation by the patient’s family physician. As with all clinical reference resources, they reflect the best understanding of the science of medicine at the time of publication, but they should be used with the clear understanding that continued research may result in new knowledge and recommendations. These guidelines are only one element in the complex process of improving the health of America. To be effective, the guidelines must be implemented.